

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS <i>Effective 4/2/07</i>	amlodipine/benazepril LOTREL (benazepril/amlodipine) TARKA (trandolapril/verapamil)	LEXXEL (enalapril/felodipine)	Each of the preferred agents must be tried for at least two weeks each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients starting therapy in this class must show a documented allergy to the preferred agents before a non-preferred agent will be authorized.
ACNE AGENTS, TOPICAL <i>Effective 4/2/07</i>	ANTIBIOTICS		A trial of 30 days of one of the preferred agents in each category will be required before a non-preferred agent will be authorized. (In cases of pregnancy, a trial of retinoids will not be required.) PA required after 17 years of age for tretinoin products.
	AKNE-MYCIN (erythromycin) clindamycin erythromycin	CLINDAGEL (clindamycin) CLINDAREACH (clindamycin) ^{NR} EVOCLIN (clindamycin)	
	RETINOIDS		
	RETIN-A MICRO (tretinoin) ^{CL} TAZORAC (tazarotene) tretinoin ^{CL}	DIFFERIN (adapalene)	
	OTHERS		
	AZELEX (azelaic acid) BENZACLIN (benzoyl peroxide/clindamycin) benzoyl peroxide CLINAC BPO (benzoyl peroxide) DUAC (benzoyl peroxide/ clindamycin) sodium sulfacetamide	BENZAMYCIN PAK (benzoyl peroxide/erythromycin) BENZIQ (benzoyl peroxide) BREVOXYL (benzoyl peroxide) erythromycin/benzoyl peroxide INOVA (benzoyl peroxide) INOVA 4/1 (benzoyl peroxide/ salicylic acid) KLARON (sodium sulfacetamide) LAVOCLIN (benzoyl peroxide) ^{NR} NEOBENZ MICRO (benzoyl peroxide) NUOX (benzoyl peroxide/sulfur) SULFOXYL (benzoyl peroxide/sulfur) TRIAZ (benzoyl peroxide) ZAQLIR (benzoyl peroxide) ZIANA (clindamycin/tretinoin) ^{NR} ZODERM (benzoyl peroxide)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.10

REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ALZHEIMER'S AGENTS <i>Effective 10/01/07</i>	CHOLINESTERASE INHIBITORS		A trial of a preferred agent will be required before a non-preferred agent In this class will be authorized. Current prescriptions for Razadyne and Razadyne ER will be grandfathered.
	ARICEPT (donepezil) ARICEPT ODT(donepezil) EXELON (rivastigmine)	COGNEX (tacrine) RAZADYNE (galantamine) RAZADYNE ER (galantamine)	
	NMDA RECEPTOR ANTAGONIST		
	NAMENDA (memantine)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral) <i>Effective 4/2/07</i>	APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone propoxyphene/APAP tramadol tramadol/APAP	ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine COMBUNOX (oxycodone/ibuprofen) DARVO CET (propoxyphene/APAP) DARVON (propoxyphene) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) ^{NR} FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LORCET, LORTAB (hydrocodone/APAP) LYNOX (oxycodone/APAP) ^{NR} meperidine OPANA (oxymorphone) OXYFAST, OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) propoxyphene TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen)	Three of the preferred agents must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Fentanyl lozenges will only be approved as an adjunct to a long-acting agent. Fentanyl lozenges will not be approved for monotherapy. Limits: Quantities exceeding 240 tablets per 30 days (8 tablets/day) for agents containing 500 mg of acetaminophen will require a prior authorization and review by the Medical Director.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.10

REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral)	DURAGESIC (fentanyl) KADIAN (morphine) methadone morphine ER	AVINZA (morphine) fentanyl MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) ULTRAM ER (tramadol)	Three preferred narcotic analgesics, including at least one long-acting agent, must be tried for at least 72 hours before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents.
ANDROGENIC AGENTS <i>Effective 10/01/07</i>	ANDRODERM (testosterone) ANDROGEL (testosterone)	TESTIM (testosterone)	The non-preferred agents will be approved only if one of the exceptions on the PA form is present.
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs) <i>Effective 4/2/07</i>	ANGIOTENSIN RECEPTOR BLOCKERS		Each of the preferred agents in the corresponding group must be tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.
	AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan)	ATACAND (candesartan) TEVETEN (eprosartan)	
	ARB COMBINATIONS		
	AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) EXFORGE (valsartan/amlodipine) ^{NR} TEVETEN-HCT (eprosartan/HCTZ)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.10

REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANGIOTENSIN MODULATORS <i>Effective 10/01/07</i>	ACE INHIBITORS		Four of the preferred agents must be tried for at least 30 days each before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALTACE (ramipril) benazepril captopril enalapril fosinopril lisinopril quinapril	ACEON (perindopril) ACCUPRIL (quinapril) CAPOTEN (captopril) LOTENSIN (benazepril) MAVIK (trandolapril) moexepiril MONOPRIL (fosinopril) PRINIVIL (lisinopril) trandolapril UNIVASC (moexepiril) VASOTEC (enalapril) ZESTRIL (lisinopril)	
	ACE INHIBITOR/DIURETIC COMBINATIONS		
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LOTENSIN HCT (benazepril/HCTZ) moexepiril/HCTZ MONOPRIL HCT (fosinopril/HCTZ) PRINZIDE (lisinopril/HCTZ) UNIRETIC (moexepiril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	
	DIRECT RENIN INHIBITORS		A thirty-day trial of one of the preferred ACE or ARB agents, at the maximum tolerable dose, is required before Tekturna will be approved.
	TEKTURNA (aliskerin)		
ANTICOAGULANTS, INJECTABLE^{CL} <i>Effective 4/2/07</i>	ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin)	INNOHEP (tinzaparin)	A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTICONVULSANTS <i>Effective 4/2/07</i>	BARBITURATES		<p>Treatment naive patients must have a trial of a preferred agent before a non-preferred agent in its corresponding class will be authorized. Patients stabilized on non-preferred agents will receive authorization to continue these drugs. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present.</p> <p>The following step therapy edits will be applied to Lyrica. Lyrica will automatically be approved if there is a history of gabapentin utilization for 60 days, with a gap in therapy of no greater than 30 days.</p> <p>Overrides for Lyrica will not be given unless the dosage of gabapentin has been maximized to 1800 mg/ 24 hour for a diagnosis of chronic or neuropathic pain.</p>
	mephobarbital phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)	
	HYDANTOINS		
	PEGANONE (ethotoin) phenytoin	DILANTIN (phenytoin) EPITOL (phenytoin) PHENYTEK (phenytoin)	
	SUCCINIMIDES		
	CELONTIN (methsuximide) ethosuximide	ZARONTIN (ethosuximide)	
	BENZODIAZEPINES		
	clonazepam DIASTAT (diazepam rectal) diazepam	KLONOPIN (clonazepam)	
	ADJUVANTS		
	carbamazepine CARBATROL (carbamazepine) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) DEPAKOTE SPRINKLE (divalproex) divalproex EQUETRO (carbamazepine) FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) KEPPRA (levetiracetam) LAMICTAL (lamotrigine) LYRICA (pregabalin) ^{CL} TOPAMAX (topiramate)	DEPAKENE (valproic acid) NEURONTIN (gabapentin) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) ZONEGRAN (zonisamide)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TRILEPTAL (oxcarbazepine) valproic acid zonisamide		
ANTIDEPRESSANTS, OTHER (second generation, non-SSRI) <i>Effective 4/2/07</i>	bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone	bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) nefazodone REMERON (mirtazapine) venlafaxine WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)	A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present. Patients on a non-preferred agent will be authorized to continue on that agent.
ANTIDEPRESSANTS, SSRIs <i>Effective 10/01/07</i>	citalopram fluoxetine fluvoxamine paroxetine sertraline	CELEXA (citalopram) LEXAPRO (escitalopram) PAXIL (paroxetine) PAXIL CR (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	A trial of two of the preferred agents will be required, for at least 30 days, before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Patients currently on a non-preferred agent will be authorized to continue on that agent. Upon hospital discharge, patients admitted with a primary mental health diagnosis and have been stabilized on a non-preferred SSRI will receive authorization to continue that drug.
ANTIEMETICS, ORAL <i>Effective 10/01/07</i>	CANNABINOIDS		Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to conventional treatments such as promethazine or ondansetron and are over 18 years of age. Marinol will be authorized only for the treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol, the prophylaxis of chemotherapy-induced nausea and vomiting unresponsive to ondansetron or promethazine and for patients between the ages of 18 and 65 years of age.
		CESAMET (nabilone) MARINOL (dronabinol)	
	5HT3 RECEPTOR BLOCKERS		A trial of Zofran is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ondansetron	ANZEMET (dolasetron)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ZOFRAN (ondansetron) ZOFRAN ODT (ondansetron)	KYTRIL (granisetron) ondansetron ODT	Quantity limits for Zofran - 14 tablets per 21 days; in cases of hyperemesis during pregnancy, increased quantities may be authorized.
	SUBSTANCE P ANTAGONISTS		Quantity limits for Emend - 12 tablets per 28 days.
	EMEND (aprepitant)		
ANTIFUNGALS, ORAL ^{CL} <i>Effective 10/01/07</i>	clotrimazole fluconazole ketoconazole MYCOSTATIN Pastilles (nystatin) nystatin terbinafine	ANCOBON (flucytosine) DIFLUCAN (fluconazole) GRIFULVIN V (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) SPORANOX (itraconazole) VFEND (voriconazole)	Non-preferred agents will be approved only if one of the exceptions on the PA form is present. PA is required when limits are exceeded. PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis.
ANTIFUNGALS, TOPICAL <i>Effective 10/01/07</i>	ANTIFUNGALS		Two of the preferred agents must be tried for at least two weeks each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	econazole ketoconazole MENTAX (butenafine) NAFTIN (naftifine) nystatin	ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) LOPROX (ciclopirox) MYCOSTATIN (nystatin) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PENLAC (ciclopirox) SPECTAZOLE (econazole) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole)	
	ANTIFUNGAL/STEROID COMBINATIONS		
	clotrimazole/betamethasone nystatin/triamcinolone	LOTRISONE (clotrimazole/betamethasone) MYCOLOG (nystatin/triamcinolone)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIHISTAMINES, MINIMALLY SEDATING <i>Effective 4/2/07</i>	ANTIHISTAMINES		A preferred agent, in the age appropriate dosage form, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALAVERT (loratadine) CLARINEX Syrup (desloratadine) loratadine TAVIST-ND (loratadine)	ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARITIN (loratadine) fexofenadine ZYRTEC (cetirizine)	
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS		
ALAVERT-D (loratadine/pseudoephedrine) loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/pseudoephedrine) CLARINEX-D (desloratadine/pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) ZYRTEC-D (cetirizine/pseudoephedrine)		
ANTIMIGRAINE AGENTS, TRIPTANS <i>Effective 4/2/07</i>	AMERGE (naratriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) RELPAX (eletriptan)	AXERT (almotriptan) FROVA (frovatriptan) ZOMIG (zolmitriptan)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Quantity limits apply for this drug class.
ANTIPARKINSON'S AGENTS (Oral) <i>Effective 10/01/07</i>	ANTICHOLINERGICS		Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents, in the corresponding class, before a non-preferred agent will be authorized. Patients currently on a non-preferred agent will be authorized to continue on that agent.
	benztropine KEMADRIN (procyclidine) trihexyphenidyl	COGENTIN (benztropine)	
	COMT INHIBITORS		
		COMTAN (entacapone) TASMAR (tolcapone)	
	DOPAMINE AGONISTS		
	REQUIP (ropinirole)	MIRAPEX (pramipexole)	
OTHER ANTIPARKINSON'S AGENTS			
carbidopa/levodopa selegiline STALEVO (levodopa/ carbidopa/entacapone)	AZILECT (rasagiline) ELDEPRYL (selegiline) PARCOPA (levodopa/carbidopa) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIPSYCHOTICS, ATYPICAL (Oral) <i>Effective 10/01/07</i>	ORAL		Treatment naïve patients for this class of drugs will be required to try a preferred agent for two weeks unless one of the exceptions on the PA form is present. Upon discharge, hospitalized patients stabilized on non-preferred agents will receive authorization to continue these drugs for labeled indications and at recommended dosages. Patients currently on Fazaclo will be authorized to continue therapy on that agent.
	clozapine GEODON (ziprasidone) INVEGA (paliperidone) RISPERDAL (risperidone) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine)	ABILIFY (aripiprazole) CLOZARIL (clozapine) FAZACLO (clozapine) ZYPREXA (olanzapine)	
	ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS		
		SYMBYAX (olanzapine/fluoxetine)	
ANTIVIRALS (Oral) <i>Effective 10/01/07</i>	ANTI-HERPES		All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	acyclovir VALTREX (valacyclovir)	FAMVIR (famciclovir) ZOVIRAX (acyclovir)	
	ANTI INFLUENZA		All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present.
	amantadine	FLUMADINE (rimantadine) rimantadine RELENZA (zanamivir) SYMMETREL (amantadine) TAMIFLU (oseltamivir)	
ATOPIC DERMATITIS <i>Effective 10/01/07</i>	ELIDEL (pimecrolimus) PROTOPIC (tacrolimus)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BETA BLOCKERS (Oral) <i>Effective 4/2/07</i>	BETA BLOCKERS		If one of the exceptions on the PA form is present or if the physician feels that the patient cannot be stabilized with any of the preferred agents, one of the non-preferred agents will be approved.
	acebutolol atenolol betaxolol bisoprolol INDERAL LA (propranolol) metoprolol nadolol pindolol propranolol sotalol timolol TOPROL XL (metoprolol)	BETAPACE (sotalol) BLOCADREN (timolol) CARTROL (carteolol) CORGARD (nadolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) ZEBETA (bisoprolol)	
	BETA- AND ALPHA- BLOCKERS		
	carvedilol COREG (carvedilol) labetalol	COREG CR (carvedilol) ^{NR} TRANDATE (labetalol)	
BLADDER RELAXANT PREPARATIONS <i>Effective 4/2/07</i>	DITROPAN XL (oxybutynin) ENABLEX (darifenacin) oxybutynin oxybutynin ER OXYTROL (oxybutynin) SANCTURA (trospium) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin)	All of the preferred agents in the class must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
BONE RESORPTION SUPPRESSION AND RELATED AGENTS <i>Effective 10/01/07</i>	BISPHOSPHONATES		One of the preferred agents must be tried for at least one month before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients currently on a non-preferred agent will be authorized to continue therapy with that agent. Evista will be approved for postmenopausal women with osteoporosis or at high risk for invasive breast cancer.
	FOSAMAX (alendronate) FOSAMAX PLUS D (alendronate/vitamin D)	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/calcium) BONIVA (ibandronate) DIDRONEL (etidronate)	
	OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS		
	MIACALCIN (calcitonin)	EVISTA (raloxifene) FORTEO (teriparatide) FORTICAL (calcitonin)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BPH AGENTS <i>Effective 4/2/07</i>	ALPHA BLOCKERS		One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	doxazosin FLOMAX (tamsulosin) terazosin UROXATRAL (alfuzosin)	CARDURA (doxazosin) CARDURA XL (doxazosin) HYTRIN (terazosin)	
	5-ALPHA-REDUCTASE (5AR) INHIBITORS		
	AVODART (dutasteride)	finasteride PROSCAR (finasteride)	
BRONCHODILATORS, ANTICHOLINERGIC <i>Effective 10/01/07</i>	ANTICHOLINERGIC		The preferred agents in the class must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)	ATROVENT Inhalation Solution (ipratropium)	
	ANTICHOLINERGIC-BETA AGONIST COMBINATIONS		For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory.
	COMBIVENT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)	
BRONCHODILATORS, BETA AGONIST <i>Effective 10/01/07</i>	INHALERS, SHORT-ACTING		All of the preferred agents in a group must be tried before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present. Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for a concurrent diagnosis of heart disease. **No PA is required for ACCUNEb for children up to 5 years of age.
	albuterol CFC MAXAIR (pirbuterol) PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol)	ALUPENT (metaproterenol) PROVENTIL (albuterol)	
	INHALERS, LONG-ACTING		
	FORADIL (formoterol)	SEREVENT (salmeterol)	
	INHALATION SOLUTION		
	albuterol	ACCUNEb (albuterol)** BROVANA (arformoterol) ^{NR} metaproterenol PROVENTIL (albuterol) XOPENEX (levalbuterol)	
	ORAL		
	albuterol terbutaline	BRETHINE (terbutaline) metaproterenol VOSPIRE ER (albuterol)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CALCIUM CHANNEL BLOCKERS (Oral) <i>Effective 4/2/07</i>	SHORT-ACTING		The preferred agents must be tried before a non-preferred agent will be approved.
	diltiazem verapamil	ADALAT (nifedipine) CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)	
CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral) <i>Effective 10/01/07</i>	BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	amoxicillin/clavulanate		
	CEPHALOSPORINS		
	cefaclor cefadroxil	CECLOR (cefaclor) CEDAX (ceftibuten)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	cefpodoxime cefprozil cefuroxime cephalexin OMNICEF (cefdinir) SPECTRACEF (cefditoren)	cefdinir CEFTIN (cefuroxime) CEFZIL (cefprozil) DURICEF (cefadroxil) KEFLEX (cephalexin) PANIXINE (cephalexin) RANICLOR (cefaclor) SUPRAX (cefixime) VANTIN (cefpodoxime)	
CYTOKINE & CAM ANTAGONISTS <small>CL</small> <i>Effective 10/01/07</i>	ENBREL (etanercept) HUMIRA (adalimumab) KINERET (anakinra) RAPTIVA (efalizumab)		
ERYTHROPOIESIS STIMULATING PROTEINS <small>CL</small> <i>Effective 4/2/07</i>	ARANESP (darbepoetin) PROCRT (rHuEPO)	EPOGEN (rHuEPO)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
FLUROQUINOLONES, ORAL <i>Effective 10/01/07</i>	AVELOX (moxifloxacin) CIPRO (ciprofloxacin) Suspension ciprofloxacin LEVAQUIN (levofloxacin) ciprofloxacin ER	CIPRO (ciprofloxacin) Tablets CIPRO XR (ciprofloxacin) FACTIVE (gemifloxacin) FLOXIN (ofloxacin) ofloxacin NOROXIN (norfloxacin) PROQUIN XR (ciprofloxacin)	One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

CL - Requires Clinical PA

NR - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Version 2007.10

REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GLUCOCORTICIDS, INHALED <i>Effective 10/01/07</i>	GLUCOCORTICIDS		All of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present. Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. When children who have been stabilized on Pulmicort Respules reach age 9, prescriptions for the Pulmicort inhaler will be authorized for them.
	AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) AZMACORT (triamcinolone) FLOVENT HFA (fluticasone) QVAR (beclomethasone)	PULMICORT (budesonide)	
	GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS		
	ADVAIR (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol)	SYMBICORT (budesonide/formoterol) ^{NR}	
GROWTH HORMONE^{CL} <i>Effective 4/2/07</i>	GENOTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) TEV-TROPIN (somatropin)	HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin) OMNITROPE (somatropin) ^{NR} ZORBTIVE (somatropin)	The preferred agents, with the exception of Saizen, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent.
HEPATITIS B TREATMENTS <i>Effective 10/01/07</i>	EPIVIR HBV (lamivudine) TYZEKA (telbivudine) HEPSERA (adefovir)	BARACLUDE	One of the preferred agents must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on the non-preferred agent will receive authorization to continue therapy on that agent.
HEPATITIS C TREATMENTS^{CL} <i>Effective 4/2/07</i>	PEGASYS (pegylated interferon) ribavirin	COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) REBETOL (ribavirin)	Patients already on a non-preferred interferon will receive authorization to continue therapy on that agent. Patients starting therapy in this class must try preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized.
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS <i>Effective 10/01/07</i>	BYETTA (exenatide) JANUMET (sitagliptin/metformin) JANUVIA (sitagliptin) SYMLIN (amylin)		Byetta and Symlin are both subject to the following step therapy edits: Byetta-Current history of therapy with a sulfonylurea, thiazolidinedione (TZD), and/or metformin No gaps of therapy greater than 30 days in the past 180 days. Symlin-History of insulin utilization in the past 90 days No gaps in therapy of greater than 30 days.

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HYPOGLYCEMICS, INSULINS <i>Effective 10/01/07</i>	HUMALOG (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine) HUMULIN (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLIN (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	APIDRA (insulin glulisine) EXUBERA (insulin)	To receive authorization for Exubera, patients must meet the following criteria: <ol style="list-style-type: none"> 1. be 18 years or older; 2. have no history of smoking in the past six months; 3. have no history of chronic lung disease in the past two years or presence of acute lower respiratory lung infection; 4. have a base line spirometry to measure FEV1. For renewal, spirometry to measure FEV1 six months after treatment initiation and then annually from second FEV1 measure; 5. have a diagnosis of Type 1 diabetes (stated or inferred) with concomitant use of a longer acting insulin; <p style="text-align: center;">OR</p> have a diagnosis of Type 2 diabetes (stated or inferred) and maximization of dosage of at least one available oral agent (sulfonylurea, metformin or thiazolidinediones), unless contraindicated; 6. have a diagnosis of lipodystrophy or needle phobia that prevents self-injection or injection by a caregiver. To receive authorization for Apidra, patients must meet the following criteria: <ol style="list-style-type: none"> 1. be 18 years or older; 2. be currently on a regimen including a longer-acting or basal insulin. 3. have had a trial of a similar preferred agent, Novolog or Humulin, with documentation that the desired results were not achieved.
HYPOGLYCEMICS, MEGLITINIDES <i>Effective 4/2/07</i>	STARLIX (nateglinide)	PRANDIN (repaglinide)	The preferred agent must be tried before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present.
HYPOGLYCEMICS, TZDS <i>Effective 4/2/07</i>	THIAZOLIDINEDIONES		
	ACTOS (pioglitazone) AVANDIA (rosiglitazone)		
	TZD COMBINATIONS		
	ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride)		
INTRANASAL RHINITIS AGENTS <i>Effective 10/01/07</i>	ANTICHOLINERGICS		All of the preferred agents, in corresponding categories, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ATROVENT (ipratropium) ipratropium		
	ANTI-HISTAMINES		
	ASTELIN (azelastine)		
	CORTICOSTEROIDS		
	FLONASE (fluticasone propionate) NASACORT AQ (triamcinolone) NASONEX (mometasone)	BECONASE AQ (beclomethasone) flunisolide fluticasone propionate NASALIDE (flunisolide) NASAREL (flunisolide) RHINOCORT AQUA (budesonide) VERAMYST (fluticasone furoate) ^{NR}	
LEUKOTRIENE MODIFIERS <i>Effective 10/01/07</i>	ACCOLATE (zafirlukast) SINGULAIR (montelukast)	ZYFLO (zileuton)	The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
LIPOTROPICS, OTHER (non-statins) <i>Effective 4/2/07</i>	BILE ACID SEQUESTRANTS		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents. Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy. If patients require the addition of Zetia to Zocor to achieve goal, use of the combination product, Vytorin, will be required. If patients are on other statins and require the addition of Zetia, patients will not be required to switch the statin that they have been using.
	cholestyramine colestipol	COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevalam)	
	CHOLESTEROL ABSORPTION INHIBITORS		
	ZETIA (ezetimibe)		
	FATTY ACIDS		
	OMACOR (omega-3-acid ethyl esters)		
	FIBRIC ACID DERIVATIVES		
	fenofibrate gemfibrozil TRICOR (fenofibrate)	ANTARA (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)	
	NIACIN		
	niacin NIASPAN (niacin)	NIACELS (niacin) NIADELAY (niacin) SLO-NIACIN (niacin)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LIPOTROPICS, STATINS <i>Effective 4/2/07</i>	STATINS		One of the preferred statins must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	ALTOPREV (lovastatin) CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin simvastatin	MEVACOR (lovastatin) PRAVACHOL (pravastatin) pravastatin ZOCOR (simvastatin)	
	STATIN COMBINATIONS		
	ADVICOR (lovastatin/niacin) VYTORIN (ezetimibe/simvastatin)	CADUET (atorvastatin/amlodipine)	
MACROLIDES/KETOLIDES (Oral) <i>Effective 10/01/07</i>	MACROLIDES		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	azithromycin clarithromycin erythromycin	BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) clarithromycin ER E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	
	KETOLIDES		Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past 28 days.
MULTIPLE SCLEROSIS AGENTS^{CL} <i>Effective 4/2/07</i>	AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer) REBIF (interferon beta-1a)		

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
NSAIDS <i>Effective 10/01/07</i>	NONSELECTIVE		The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	diclofenac etodolac fenoprofen flurbiprofen ibuprofen (Rx and OTC) indomethacin ketorolac naproxen (Rx only) oxaprozin piroxicam sulindac	ADVIL (ibuprofen) ANAPROX (naproxen) ANSAID (flurbiprofen) CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) FELDENE (piroxicam) INDOCIN (indomethacin) ketoprofen LODINE (etodolac) meclofenamate mefenamic acid MOTRIN (ibuprofen) nabumetone NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) NUPRIN (ibuprofen) ORUDIS (ketoprofen) PONSTEL (meclofenamate) tolmetin VOLTAREN (diclofenac)	
	NSAID/GI PROTECTANT COMBINATIONS		
		ARTHROTEC (diclofenac/misoprostol) PREVACID NAPRAPAC (naproxen/lansoprazole)	
OPHTHALMIC FLUOROQUINOLONES <i>Effective 10/01/07</i>	COX-II SELECTIVE^{CL}		COX-II selective NSAIDs will be approved for patients with a GI Risk Score of ≥ 13 .
	ciprofloxacin ofloxacin VIGAMOX (moxifloxacin)	CILOXAN (ciprofloxacin) OCUFLOX (ofloxacin) QUIXIN (levofloxacin) ZYMAR (gatifloxacin)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS <i>Effective 10/01/07</i>	ACULAR (ketorolac) ALAWAY (ketotifen) ALREX (loteprednol) cromolyn ELESTAT (epinastine) OPTIVAR (azelastine) PATADAY (olopatadine) PATANOL (olopatadine) ZADITOR OTC (ketotifen)	ALOCRIL (nedocromil) ALAMAST (pemirolast) ALOMIDE (Iodoxamide) CROLOM (cromolyn) EMADINE (emedastine) ketotifen OPTICROM (cromolyn)	Two of the preferred agents must be tried before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present.
OPHTHALMICS, GLAUCOMA AGENTS <i>Effective 10/01/07</i>	PARASYMPATHOMIMETICS		Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.
CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine		ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine)	
SYMPATHOMIMETICS		ALPHAGAN P (brimonidine) brimonidine dipivefrin	
BETA BLOCKERS		BETAGAN (levobunolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol)	
CARBONIC ANHYDRASE INHIBITORS		AZOPT (brinzolamide) TRUSOPT (dorzolamide)	
PROSTAGLANDIN ANALOGS		XALATAN (latanoprost)	
COMBINATION AGENTS		COSOPT (dorzolamide/timolol)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
OPHTHALMIC NSAIDS <i>Effective 10/01/07</i>	flurbiprofen ACULAR LS (ketorolac) ACULAR PF (ketorolac) XIBROM (bromfenac) NEVANAC (nepafenac)	diclofenac	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
OTIC FLUOROQUINOLONES <i>Effective 4/2/07</i>	CIPRODEX (ciprofloxacin/dexamethasone) FLOXIN (ofloxacin)	CIPRO HC (ciprofloxacin/hydrocortisone)	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PHOSPHATE BINDERS <i>Effective 4/2/07</i>	FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer)		
PLATELET AGGREGATION INHIBITORS <i>Effective 10/01/07</i>	AGGRENOX (dipyridamole/ASA) PLAVIX (clopidogrel)	dipyridamole PERSANTINE (dipyridamole) TICLID (ticlopidine) ticlopidine	All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present.
PROTON PUMP INHIBITORS (Oral) <i>Effective 4/2/07</i>	NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole)	ACIPHEX (rabeprazole) omeprazole PREVACID Solu-Tabs (lansoprazole) PREVACID Suspension (lansoprazole) PRILOSEC (omeprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate)	The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age.
SEDATIVE HYPNOTICS <i>Effective 4/2/07</i>	BENZODIAZEPINES		The preferred agent must be tried for 14 days before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.
	temazepam	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) triazolam	
	OTHERS		
	zolpidem	AMBIEN (zolpidem)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

**REVISED 10/26/07
Implementation Date: 10/01/07
Originally Posted: 9/13/07**

Version 2007.10

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon)	
STIMULANTS AND RELATED AGENTS <i>Effective 10/01/07</i>	<p align="center">AMPHETAMINES</p> ADDERALL XR (amphetamine salt combination) amphetamine salt combination dextroamphetamine	ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) DEXTROSTAT (dextroamphetamine) VYVANSE (lisdexamphetamine) ^{NR}	<p>Except for Strattera, PA is required for adults >18 years.</p> <p>One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried before a non-preferred agent will be authorized.</p> <p>Amphetamines will be authorized for the treatment of depression only after documented failure of multiple antidepressants.</p> <p>Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy.</p> <p>Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for 30 days or less for tapering purposes. Only two doses of each strength, or two concurrent doses of any strength, and a maximum of one dose of a 60 mg capsule, will be approved in a 34-day period.</p>
ULCERATIVE COLITIS AGENTS <i>Effective 4/2/07</i>	<p align="center">ORAL</p> ASACOL (mesalamine) COLAZAL (balsalazide) DIPENTUM (olsalazine) PENTASA (mesalamine) sulfasalazine	AZULFIDINE (sulfasalazine) LIALDA (mesalamine) ^{NR}	<p>The preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present.</p>
	<p align="center">RECTAL</p> CANASA (mesalamine) mesalamine	ROWASA (mesalamine)	

Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.

^{CL} - Requires Clinical PA

^{NR} - New drug has not been reviewed by P & T Committee